Novel JAK‐1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report

International Journal of Rheumatic DiseasesVolume 26, Issue 11 p. 2335-2337 CORRESPONDENCE Novel JAK-1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report Mingwei Ma, Mingwei Ma School of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSearch for more papers by this authorSiyi Lu, Siyi Lu Department of Rheumatology, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, ChinaSearch for more papers by this authorXiujuan Hou, Xiujuan Hou orcid.org/0000-0002-1236-6849 Department of Rheumatology, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, ChinaSearch for more papers by this authorChen Li, Corresponding Author Chen Li [email protected] orcid.org/0000-0002-8527-1680 Department of Rheumatology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China Correspondence Chen Li, Department of Rheumatology, Fangshan Hospital, Beijing University of Chinese Medicine, 4, Chengguan Health Road, Fangshan District, Beijing, China. Email: [email protected]Search for more papers by this author Mingwei Ma, Mingwei Ma School of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaSearch for more papers by this authorSiyi Lu, Siyi Lu Department of Rheumatology, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, ChinaSearch for more papers by this authorXiujuan Hou, Xiujuan Hou orcid.org/0000-0002-1236-6849 Department of Rheumatology, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, ChinaSearch for more papers by this authorChen Li, Corresponding Author Chen Li [email protected] orcid.org/0000-0002-8527-1680 Department of Rheumatology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China Correspondence Chen Li, Department of Rheumatology, Fangshan Hospital, Beijing University of Chinese Medicine, 4, Chengguan Health Road, Fangshan District, Beijing, China. Email: [email protected]Search for more papers by this author First published: 07 June 2023 https://doi.org/10.1111/1756-185X.14774Citations: 1 Mingwei Ma and Siyi Lu contributed equally to this study. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clin Rheumatol. 1994; 8(2): 333-362. 10.1016/S0950-3579(94)80022-7 CASPubMedWeb of Science®Google Scholar 2Liu S, Tang M, Cao Y, Li C. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update. Ther Adv Musculoskelet Dis. 2020; 12:1759720x20912865. 10.1177/1759720X20912865 PubMedWeb of Science®Google Scholar 3Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, et al. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford). 2008; 47(8): 1160-1167. 10.1093/rheumatology/ken185 CASPubMedWeb of Science®Google Scholar 4Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017; 77(5): 521-546. 10.1007/s40265-017-0701-9 CASPubMedWeb of Science®Google Scholar 5Yuan F, Luo J, Yang Q. SAPHO syndrome complicated by ankylosing spondylitis successfully treated with Tofacitinib: a case report. Front Immunol. 2022; 13:911922. 10.3389/fimmu.2022.911922 CASPubMedWeb of Science®Google Scholar 6Fleischmann R, Mysler E, Bessette L, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2022; 8(1):e002012. 10.1136/rmdopen-2021-002012 PubMedWeb of Science®Google Scholar 7Nash P, Richette P, Gossec L, et al. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022; 61(8): 3257-3268. 10.1093/rheumatology/keab905 CASPubMedWeb of Science®Google Scholar 8Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of Upadacitinib vs Dupilumab in adults with moderate-to-severe atopic dermatitis. JAMA Dermatol. 2021; 157(9): 1047-1055. 10.1001/jamadermatol.2021.3023 PubMedWeb of Science®Google Scholar Citing Literature Volume26, Issue11November 2023Pages 2335-2337 ReferencesRelatedInformation